Journal
ANTIVIRAL RESEARCH
Volume 78, Issue 1, Pages 103-115Publisher
ELSEVIER
DOI: 10.1016/j.antiviral.2007.11.003
Keywords
Lassa virus; Lassa fever; Arenavirus; viral hemorrhagic fever; West Africa; antiviral therapy; ribavirin; pathogenesis
Categories
Ask authors/readers for more resources
Unlike many viral hemorrhagic fevers (VHFs), Lassa fever (LF) is not a rare disease that emerges only as sporadic cases or in outbreak form. Although surveillance is inadequate to determine the true incidence, up to 300,000 infections and 5000 deaths from LF are estimated to occur yearly. The highest incidence is in the Mano River Union (MRU) countries of Sierra Leone, Liberia, and Guinea. Although civil unrest in this region over the past two decades has impeded capacity building and research, new-found peace in recent years presents new opportunities. In 2004, the Mano River Union Lassa Fever Network (MRU LFN) was established to assist NIRU countries in the development of national and regional surveillance, diagnosis, treatment, control, and prevention of LF. Here, we review the present literature on treatment and pathogenesis of LF and outline priorities for future research in the field made possible by the improved research capacity of the MRU LFN. (C) 2007 Elsevier B.V. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available